Targeted Nuclear Imaging of Breast Cancer: Status of Radiotracer Development and Clinical Applications

2012 ◽  
Vol 27 (2) ◽  
pp. 105-112 ◽  
Author(s):  
Fan-Lin Kong ◽  
E. Edmund Kim ◽  
David J. Yang
2020 ◽  
Vol 16 (34) ◽  
pp. 2863-2878
Author(s):  
Yang Liu ◽  
Qian Du ◽  
Dan Sun ◽  
Ruiying Han ◽  
Mengmeng Teng ◽  
...  

Breast cancer is one of the leading causes of cancer-related deaths in women worldwide. Unfortunately, treatments often fail because of the development of drug resistance, the underlying mechanisms of which remain unclear. Circulating tumor DNA (ctDNA) is free DNA released into the blood by necrosis, apoptosis or direct secretion by tumor cells. In contrast to repeated, highly invasive tumor biopsies, ctDNA reflects all molecular alterations of tumors dynamically and captures both spatial and temporal tumor heterogeneity. Highly sensitive technologies, including personalized digital PCR and deep sequencing, make it possible to monitor response to therapies, predict drug resistance and tailor treatment regimens by identifying the genomic alteration profile of ctDNA, thereby achieving precision medicine. This review focuses on the current status of ctDNA biology, the technologies used to detect ctDNA and the potential clinical applications of identifying drug resistance mechanisms by detecting tumor-specific genomic alterations in breast cancer.


Author(s):  
Erin F. Cobain ◽  
Costanza Paoletti ◽  
Jeffrey B. Smerage ◽  
Daniel F. Hayes

2022 ◽  
pp. 85-104
Author(s):  
Mena Asha Krishnan ◽  
Amulya Cherukumudi ◽  
Sibi Oommen ◽  
Sumeet Suresh Malapure ◽  
Venkatesh Chelvam

2010 ◽  
Vol 2 (38) ◽  
pp. 38ps32-38ps32
Author(s):  
H. M. Horlings ◽  
C. D. Savci-Heijink ◽  
M. J. van de Vijver

Meta Gene ◽  
2018 ◽  
Vol 17 ◽  
pp. S12
Author(s):  
Bodour Salhia ◽  
Gerald Gooden ◽  
Tim Triche

2020 ◽  
Vol 10 (9) ◽  
pp. 3311
Author(s):  
Maggie Banys-Paluchowski ◽  
Florian Reinhardt ◽  
Tanja Fehm

Circulating tumor cells (CTCs) have gained importance as an emerging biomarker in solid tumors in the last two decades. Several detection assays have been introduced by various study groups, with EpCAM-based CellSearch system being the most widely used and standardized technique. In breast cancer, detection of CTCs correlates with clinical outcome in early and metastatic settings. CTC persistence beyond first cycle of palliative chemotherapy indicates poor response to treatment in metastatic situation. Beyond prognostication and therapy monitoring, CTC counts can guide treatment decisions in hormone receptor positive HER2-negative metastatic breast cancer. Furthermore, CTC-based therapy interventions are currently under investigation in clinical trials. In this review, we focus on the current state of knowledge and possible clinical applications of CTC diagnostics in patients with metastatic breast cancer.


2020 ◽  
Vol 7 (4) ◽  
pp. 124 ◽  
Author(s):  
Jun Yang ◽  
Gokhan Bahcecioglu ◽  
Pinar Zorlutuna

Emerging evidence has shown multiple roles of the tumor microenvironment (TME) components, specifically the extracellular matrix (ECM), in breast cancer development, progression, and metastasis. Aside from the biophysical properties and biochemical composition of the breast ECM, the signaling molecules are extremely important in maintaining homeostasis, and in the breast TME, they serve as the key components that facilitate tumor progression and immune evasion. Extracellular vesicles (EVs), the mediators that convey messages between the cells and their microenvironment through signaling molecules, have just started to capture attention in breast cancer research. In this comprehensive review, we first provide an overview of the impact of ECM in breast cancer progression as well as the alterations occurring in the TME during this process. The critical importance of EVs and their biomolecular contents in breast cancer progression and metastasis are also discussed. Finally, we discuss the potential biomedical or clinical applications of these extracellular components, as well as how they impact treatment outcomes.


Immunotherapy ◽  
2014 ◽  
Vol 6 (3) ◽  
pp. 349-360 ◽  
Author(s):  
Lucia Gelao ◽  
Carmen Criscitiello ◽  
Angela Esposito ◽  
Michele De Laurentiis ◽  
Luca Fumagalli ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document